Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first‑line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS).
S. Siena
Consultant or Advisory Role - Amgen; AstraZeneca; Merck Serono; Roche
J. Cassidy
Consultant or Advisory Role - Amgen
Research Funding - Amgen
J. Tabernero
Consultant or Advisory Role - Amgen; ImClone Systems; Merck Serono; Roche
R. L. Burkes
Consultant or Advisory Role - Amgen
Honoraria - Amgen
M. E. Barugel
Consultant or Advisory Role - Amgen; Roche
Honoraria - Roche
Y. Humblet
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
D. Cunningham
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
F. Xu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
K. Krishnan
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
J. Douillard
Consultant or Advisory Role - Amgen
Honoraria - Amgen